| Alaaddin Hasan Kandeel, MD | |
|
400 E 3rd St, Essentia Health Duluth Clinic, Duluth, MN 55805-1951 | |
| (218) 786-8364 | |
| Not Available |
| Full Name | Alaaddin Hasan Kandeel |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 32 Years |
| Location | 400 E 3rd St, Duluth, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003110008 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 257049-1 (New York) | Secondary |
| 207K00000X | Allergy & Immunology | 56325 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Essentia Health Duluth | Duluth, MN | Hospital |
| St Marys Hospital Superior | Superior, WI | Hospital |
| Essentia Health Virginia | Virginia, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Essentia Health Virginia Llc | 7810149002 | 57 |
| The Duluth Clinic Ltd | 2567374283 | 932 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced receipt from Mallinckrodt Inc., a Covidien company (Covidien), of top-line results from a Phase 2 study conducted by Covidien, of twice-daily administration of PENNSAID Viscous Solution (topical diclofenac sodium viscous solution) 2% w/w, previously referred to as PENNSAID Gel.
In a study of stroke patients, investigators confirmed through MRI brain scans that there was an association between the extent of disruption to the brain's protective blood-brain barrier and the severity of bleeding following invasive stroke therapy. The results of the National Institutes of Health-funded study were published in Neurology.
The Multiple Myeloma Research Foundation (MMRF) today announced that two San Diego area biotech firms, Intellikine and Tragara Pharmaceuticals, Inc. will receive funding via its MMRF Biotech Investment Award program. The MMRF Biotech Investment Awards represent a multi-year research grant commitment to fund the early-stage drug development of novel compounds and approaches that show potential in treating multiple myeloma. Based on the companies' achievement of clearly defined milestones, the MMRF will commit a total of $1,000,000 to each company by the end of 2011.
GlaxoSmithKline (GSK) plans to decrease the prices of many of its leading medicines in emerging markets following the success of a pilot program in the Philippines, Andrew Witty, GSK's chief executive, said, Financial Times reports. Witty said the price cuts are part of an effort to diversify and expand globally.
The American Autoimmune Related Diseases Association, a national nonprofit health organization dedicated to increasing awareness of autoimmune diseases, today issued a white paper to educate its membership and the patient community about biosimilar medicines after a survey found most patients were generally unaware of this new category of medicines which may soon be approved in the U.S.
› Verified 5 days ago
| Entity Name | The Duluth Clinic Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902563638 PECOS PAC ID: 2567374283 Enrollment ID: O20031103000229 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced receipt from Mallinckrodt Inc., a Covidien company (Covidien), of top-line results from a Phase 2 study conducted by Covidien, of twice-daily administration of PENNSAID Viscous Solution (topical diclofenac sodium viscous solution) 2% w/w, previously referred to as PENNSAID Gel.
In a study of stroke patients, investigators confirmed through MRI brain scans that there was an association between the extent of disruption to the brain's protective blood-brain barrier and the severity of bleeding following invasive stroke therapy. The results of the National Institutes of Health-funded study were published in Neurology.
The Multiple Myeloma Research Foundation (MMRF) today announced that two San Diego area biotech firms, Intellikine and Tragara Pharmaceuticals, Inc. will receive funding via its MMRF Biotech Investment Award program. The MMRF Biotech Investment Awards represent a multi-year research grant commitment to fund the early-stage drug development of novel compounds and approaches that show potential in treating multiple myeloma. Based on the companies' achievement of clearly defined milestones, the MMRF will commit a total of $1,000,000 to each company by the end of 2011.
GlaxoSmithKline (GSK) plans to decrease the prices of many of its leading medicines in emerging markets following the success of a pilot program in the Philippines, Andrew Witty, GSK's chief executive, said, Financial Times reports. Witty said the price cuts are part of an effort to diversify and expand globally.
The American Autoimmune Related Diseases Association, a national nonprofit health organization dedicated to increasing awareness of autoimmune diseases, today issued a white paper to educate its membership and the patient community about biosimilar medicines after a survey found most patients were generally unaware of this new category of medicines which may soon be approved in the U.S.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alaaddin Hasan Kandeel, MD 400 E 3rd St, Essentia Health Duluth Clinic, Duluth, MN 55805-1951 Ph: (218) 786-8364 | Alaaddin Hasan Kandeel, MD 400 E 3rd St, Essentia Health Duluth Clinic, Duluth, MN 55805-1951 Ph: (218) 786-8364 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced receipt from Mallinckrodt Inc., a Covidien company (Covidien), of top-line results from a Phase 2 study conducted by Covidien, of twice-daily administration of PENNSAID Viscous Solution (topical diclofenac sodium viscous solution) 2% w/w, previously referred to as PENNSAID Gel.
In a study of stroke patients, investigators confirmed through MRI brain scans that there was an association between the extent of disruption to the brain's protective blood-brain barrier and the severity of bleeding following invasive stroke therapy. The results of the National Institutes of Health-funded study were published in Neurology.
The Multiple Myeloma Research Foundation (MMRF) today announced that two San Diego area biotech firms, Intellikine and Tragara Pharmaceuticals, Inc. will receive funding via its MMRF Biotech Investment Award program. The MMRF Biotech Investment Awards represent a multi-year research grant commitment to fund the early-stage drug development of novel compounds and approaches that show potential in treating multiple myeloma. Based on the companies' achievement of clearly defined milestones, the MMRF will commit a total of $1,000,000 to each company by the end of 2011.
GlaxoSmithKline (GSK) plans to decrease the prices of many of its leading medicines in emerging markets following the success of a pilot program in the Philippines, Andrew Witty, GSK's chief executive, said, Financial Times reports. Witty said the price cuts are part of an effort to diversify and expand globally.
The American Autoimmune Related Diseases Association, a national nonprofit health organization dedicated to increasing awareness of autoimmune diseases, today issued a white paper to educate its membership and the patient community about biosimilar medicines after a survey found most patients were generally unaware of this new category of medicines which may soon be approved in the U.S.
› Verified 5 days ago
Dr. Kristi L Monson, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 920 E 1st St, Ste P201, Duluth, MN 55805 Phone: 218-249-7920 |